Perrigo (PRGO) Stock Overview
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
PRGO Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Perrigo Company plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.66 |
| 52 Week High | US$22.65 |
| 52 Week Low | US$9.23 |
| Beta | 0.60 |
| 1 Month Change | 7.64% |
| 3 Month Change | 24.29% |
| 1 Year Change | -38.66% |
| 3 Year Change | -59.27% |
| 5 Year Change | -68.91% |
| Change since IPO | 17.51% |
Recent News & Updates
Seeking Alpha • Aug 13
Perrigo: The Rebound Is Just Getting Started
Summary Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return. Dividend yield above 9% and the potential for multiple expansion support the thesis of doubling capital in five years. Read the full article on Seeking AlphaAnalysis Article • Aug 08
Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders will be ecstatic, with their stake up 27% over the past week following Perrigo Company plc 's ( NYSE:PRGO...Recent updates
Seeking Alpha • Aug 13
Perrigo: The Rebound Is Just Getting Started
Summary Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return. Dividend yield above 9% and the potential for multiple expansion support the thesis of doubling capital in five years. Read the full article on Seeking AlphaAnalysis Article • Aug 08
Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders will be ecstatic, with their stake up 27% over the past week following Perrigo Company plc 's ( NYSE:PRGO...
Narrative Update • Jul 02
PRGO: Index Shift And CEO Transition Will Shape Future Upside Potential
Analysts have reduced their price target for Perrigo to $20 from $28. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
Narrative Update • Jun 18
PRGO: Leadership Reset And Infant Nutrition Headwinds Will Shape Future Earnings Power
The Perrigo fair value estimate has been revised from $15.00 to $14.00 as analysts incorporate slightly higher discount rates, modestly weaker revenue and margin assumptions, and a small adjustment to future P/E expectations into their price target work. Analyst Commentary Analysts covering Perrigo are incorporating a more conservative set of assumptions around revenue growth, margins, discount rates, and future P/E multiples, which is reflected in the updated US$14.00 fair value estimate.
Narrative Update • Jun 03
PRGO: Future Upside Will Rely On Infant Nutrition Execution
Analysts have modestly raised their price target on Perrigo to $16.50, citing updated assumptions for the discount rate and future P/E while keeping fair value and long term growth expectations essentially unchanged. Analyst Commentary Recent commentary around valuation work for Perrigo focuses on how updated discount rate and P/E assumptions affect the risk and return profile rather than changing the core business outlook.Narrative Update • May 09
PRGO: Future Upside Will Hinge On Infant Nutrition Turnaround
Analysts have trimmed the Perrigo price target to $16.50 from $17. This reflects updated views on modest revenue growth potential, slightly lower profit margins, and a higher assumed future P/E multiple, while keeping the discount rate essentially unchanged.Narrative Update • Apr 22
PRGO: Future Upside Will Depend On Infant Nutrition Recovery Trajectory
Analysts have trimmed their price targets on Perrigo to a range of about $15 to $17, reflecting updated views on softer infant nutrition trends, along with ongoing share gains in private label and key branded products. Analyst Commentary Recent research on Perrigo centers on how well management can balance areas of weakness in infant nutrition with ongoing share gains in private label and key branded products, and how that balance feeds into valuation around the mid-teens price target range.Narrative Update • Apr 08
PRGO: Future Upside Will Depend On Infant Nutrition Recovery And Share Gains
Analysts have reduced Perrigo's average price target by $3, citing continued pressure in the infant nutrition business, while other product lines show steadier performance and share gains. Analyst Commentary Recent commentary on Perrigo focuses on how management is handling pressure in infant nutrition while trying to keep the rest of the portfolio on track.Narrative Update • Mar 25
PRGO: Infant Nutrition Headwinds Will Shape Future Earnings Power Narrative
Analysts have reduced the Perrigo price target to $15 from $27, reflecting updated assumptions for lower revenue growth, slimmer profit margins, a higher discount rate, and a higher future P/E multiple in their models. Analyst Commentary Across recent research updates, bearish analysts have taken a more cautious stance on Perrigo, concentrating on where execution and growth trends may not fully support prior valuation assumptions.Narrative Update • Mar 09
PRGO: Future Upside Will Hinge On Infant Nutrition Business Stabilization
Perrigo's updated analyst price target has been reduced from $21 to $17, as analysts factor in softer revenue expectations, lower projected profit margins, a higher discount rate, and recent Street research pointing to pressure in the infant nutrition business even as other segments hold up. Analyst Commentary Recent Street research on Perrigo points to a mixed setup, with price targets moving lower but differing views on how much of the pressure is already reflected in valuation.Narrative Update • Feb 23
PRGO: Index Reclassification And Modeling Shifts Will Shape Future Upside Potential
Narrative Update on Perrigo Analysts kept their Perrigo fair value estimate steady at $28.00 while slightly adjusting inputs such as discount rate, revenue growth, profit margin, and future P/E. This reflects updated modeling rather than a major shift in their outlook.Narrative Update • Feb 08
PRGO: Index Reclassification And Lawsuit Risk Will Shape Future Upside Potential
Analysts have reduced their price target on Perrigo from US$40 to US$28, citing updated assumptions that reflect a higher discount rate, more muted revenue growth and profit margins, and a modestly higher future P/E multiple in line with broader sector target resets. Analyst Commentary Bullish analysts looking at companies with adjusted price targets are generally focusing on how revised assumptions around discount rates, growth, and margins flow through to valuation, rather than short term share price moves.Narrative Update • Jan 25
PRGO: Future Upside Will Depend On Infant Nutrition Business Review Execution
Narrative Update The analyst price target on Perrigo has been reduced by $12 to $20. Analysts are factoring in slower infant formula recovery, competitive pressure, and less certain over-the-counter trends, which are contributing to slightly weaker growth, margins, and a higher assumed future P/E multiple.Narrative Update • Jan 11
PRGO: Future Upside Will Hinge On Infant Nutrition Business Review Execution
Narrative Update: Perrigo Analysts have cut their price target on Perrigo to $20 from $32, reflecting reduced revenue growth and profit margin expectations, slower progress in the infant formula and over the counter businesses, and a modest adjustment to the assumed future P/E multiple. Analyst Commentary The recent reset in expectations on Perrigo centers on slower progress in key growth areas and a reassessment of what investors are willing to pay for the shares, reflected in the lower price target to $20 from $32 and a downgrade to Neutral by JPMorgan following the Q3 report.Narrative Update • Dec 27
PRGO: Future Upside Will Depend On Infant Formula Recovery Execution
Analysts have modestly reduced their price target on Perrigo to $21.00 from $21.50, citing increased near term business uncertainty, a slower than expected recovery in infant formula amid heightened competition, and mixed over the counter market trends. Analyst Commentary Recent commentary from JPMorgan underscores a shift to a more cautious stance on Perrigo, with the firm cutting its rating to Neutral and trimming its price target to $20 from $32 following the Q3 report.Narrative Update • Dec 13
PRGO: Future Upside Will Depend On Infant Formula Business Resolution
Analysts have lowered their price target on Perrigo to $20 from $32 as they factor in slower than expected recovery in the infant formula segment, rising competitive pressures, and increased uncertainty around over the counter market trends over the next year. Analyst Commentary Bullish analysts highlight that Perrigo's core franchise remains intact despite near term turbulence.Narrative Update • Nov 28
PRGO: Future Recovery Will Depend On Resolution Of Infant Formula Challenges
Analysts have lowered their price target for Perrigo from $32 to $20, citing increased uncertainty and a slower than expected recovery in the company's infant formula business as key factors behind the shift. Analyst Commentary Analysts have provided mixed commentary on Perrigo following its recent quarterly report, reflecting both opportunities and challenges that could influence the company's valuation and long-term growth prospects.Narrative Update • Nov 14
PRGO: Recovery Momentum Will Improve As Infant Formula Pressures Ease
Analysts have lowered their price target for Perrigo from $32.50 to $21.50 per share. They cite increased uncertainty around recovery in the infant formula business and challenging trends in the over-the-counter market.Analysis Article • Nov 07
Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31%
Perrigo Company plc ( NYSE:PRGO ) shareholders that were waiting for something to happen have been dealt a blow with a...Narrative Update • Oct 31
PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential
Analysts have lowered their price target for Perrigo from $33.50 to $32.50. They cite modestly slower projected revenue growth, although profit margins and discount rate assumptions remain stable.Narrative Update • Oct 16
Store-brand Adoption And Self-Care Trends Will Expand The OTC Market
Narrative Update on Perrigo Price Target Analysts have lowered their price target for Perrigo from $34.25 to $33.50. They cite minor shifts in projected revenue growth and discount rates as key inputs for this downward revision.Narrative Update • Aug 08
Store-brand Adoption And Self-Care Trends Will Expand The OTC Market
With both Perrigo’s discount rate and future P/E multiple remaining effectively unchanged, analysts have held their consensus price target steady at $34.25. What's in the News Perrigo reaffirmed fiscal year 2025 earnings guidance, expecting reported net sales growth of 0% to 3% and organic net sales growth of 1.5% to 4.5%.Analysis Article • Jun 25
Insufficient Growth At Perrigo Company plc (NYSE:PRGO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 0.8x Perrigo Company plc ( NYSE:PRGO ) may be sending very bullish signals at...New Narrative • May 11
Americas Awards And Supply Chain Savings Will Fuel Future Performance
Strategic investments in OTC brands and enhanced supply chain efficiencies are poised to improve Perrigo's operating margins and revenue growth.Analysis Article • Apr 28
Is Perrigo (NYSE:PRGO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 24
Perrigo: Opill Shows Where The Company Wants To Be
Summary Perrigo's transformation from a low-margin generics manufacturer to a branded consumer self-care company hinges on the success of products like Opill and Mederma. Despite short-term revenue declines, Perrigo's margin expansion and cost-saving initiatives show promise for long-term growth and strategic focus. The company's financial health is under pressure, with high leverage and volatile infant formula business posing significant risks. PRGO is a potential buy for long-term investors willing to accept the risks and rewards of a company in transition. Read the full article on Seeking AlphaAnalysis Article • Feb 28
Perrigo's (NYSE:PRGO) Shareholders Will Receive A Bigger Dividend Than Last Year
Perrigo Company plc's ( NYSE:PRGO ) periodic dividend will be increasing on the 25th of March to $0.29, with investors...Analysis Article • Feb 06
Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.8x Perrigo Company plc ( NYSE:PRGO ) may be sending bullish signals at the...Seeking Alpha • Jan 28
Perrigo Paves The Way For Recovery With Margin Focus
Summary Perrigo is a focused OTC consumer healthcare player, slimming down operations and enhancing margins under new management, with a 4.6% dividend yield. Despite short-term pressures from a weak cold-and-flu season and infant formula production issues, PRGO is positioned for recovery and growth by 2026. The company is exploring new markets with a 'disruptive growth' team, focusing on women's health and GLP-1 side effect relief, aiming for mid-single-digit growth. PRGO's Project Energize targets $150 million in annual savings by 2026, with significant debt management and a stable dividend, making it a solid dividend stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Perrigo: A Consumer Health Company Close To An Inflection Point
Summary Perrigo's strategic focus on consumer self-care products and divestment of non-core assets positions it for strong growth and higher margins. The company's extensive product range and regulatory expertise provide a competitive advantage, especially in the OTC pharmaceutical market. Recent management changes and operational improvements, including cost-cutting initiatives and supply chain optimization, are expected to drive significant earnings growth. Perrigo's launch of Opill, the first OTC birth control pill, and the turnaround of its infant formula business, present substantial future growth opportunities. Read the full article on Seeking AlphaAnalysis Article • Dec 06
Is Perrigo (NYSE:PRGO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| PRGO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.4% | -4.0% | -2.2% |
| 1Y | -38.7% | 43.7% | 13.1% |
Return vs Industry: PRGO underperformed the US Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: PRGO underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| PRGO volatility | |
|---|---|
| PRGO Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PRGO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRGO's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 8,100 | Albert Manzone | www.perrigo.com |
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Perrigo Company plc Fundamentals Summary
| PRGO fundamental statistics | |
|---|---|
| Market cap | US$1.89b |
| Earnings (TTM) | -US$1.70b |
| Revenue (TTM) | US$4.14b |
0.5x
P/S Ratio-1.1x
P/E RatioIs PRGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRGO income statement (TTM) | |
|---|---|
| Revenue | US$4.14b |
| Cost of Revenue | US$2.77b |
| Gross Profit | US$1.38b |
| Other Expenses | US$3.08b |
| Earnings | -US$1.70b |
Last Reported Earnings
Jun 27, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.27 |
| Gross Margin | 33.26% |
| Net Profit Margin | -41.09% |
| Debt/Equity Ratio | 131.2% |
How did PRGO perform over the long term?
See historical performance and comparisonDividends
8.5%
Current Dividend Yield-9%
Payout RatioDoes PRGO pay a reliable dividends?
See PRGO dividend history and benchmarks| Perrigo dividend dates | |
|---|---|
| Ex Dividend Date | Aug 28 2026 |
| Dividend Pay Date | Sep 15 2026 |
| Days until Ex dividend | 15 days |
| Days until Dividend pay date | 3 days |
Does PRGO pay a reliable dividends?
See PRGO dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 21:50 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/27 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perrigo Company plc is covered by 32 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Douglas Tsao | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |